- Conditions
- Metastatic Melanoma
- Interventions
- Not listed
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1825–1848
of 2,209
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Lung Cancer, Melanoma (Skin)
- Interventions
- COVID-19 Vaccine
- Biological
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Melanoma
- Interventions
- SSE educational intervention, Active control:Healthy Living
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Uveal Melanoma
- Interventions
- Not listed
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Metastatic Melanoma
- Interventions
- Secukinumab Injection
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Melanoma
- Interventions
- Smartphone
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Melanoma (Skin)
- Interventions
- everolimus
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 94
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 60 more
- Conditions
- Unresected Stage IIIb to IVM1c Melanoma
- Interventions
- Talimogene Laherparepvec
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Melanoma
- Interventions
- APX005M, Pembrolizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stage IV Melanoma, Stage III Melanoma
- Interventions
- Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC), Autologous PBMCs in GM-CSF (MC)
- Biological
- Lead sponsor
- Lisata Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 18
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 14 more
- Conditions
- Uveal Melanoma
- Interventions
- Crizotinib
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Miami Beach, Florida • New York, New York • Columbus, Ohio
- Conditions
- Metastatic Melanoma
- Interventions
- Antimelanoma injection of GSL alpha-Gal
- Biological
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Melanoma
- Interventions
- YM155, Docetaxel
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 12
- States / cities
- Mobile, Alabama • Tuscon, Arizona • Los Angeles, California + 6 more
- Conditions
- Melanoma
- Interventions
- Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab
- Biological · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor
- Interventions
- WTX-124, pembrolizumab
- Drug
- Lead sponsor
- Werewolf Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more
- Conditions
- Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Interventions
- APX005M, Cabiralizumab, Nivolumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Melanoma (Skin)
- Interventions
- MAGE-10.A2, MART-1 antigen, NY-ESO-1 peptide vaccine, sargramostim, tyrosinase peptide
- Biological
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma
- Interventions
- 6MHP, Montanide ISA-51, polyICLC, CDX-1127
- Biological · Drug
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Charlottesville, Virginia • Richmond, Virginia
- Conditions
- Metastatic Cancer, Metastatic Melanoma, Renal Cancer
- Interventions
- Anti-VEGFR2 CAR CD8 plus PBL, Cyclophosphamide, Aldesleukin, Fludarabine
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Interventions
- trametinib, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Advanced Non-hematologic Malignancies, Advanced Metastatic Melanoma
- Interventions
- TAK-733
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Detriot, Michigan • Buffalo, New York
- Conditions
- Skin Cancer, Metastatic Melanoma
- Interventions
- Fludarabine, Cyclophosphamide, IL-12 transduced TIL
- Drug · Biological
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Malignant Melanoma
- Interventions
- pembrolizumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania